Evidence mapPaperPMID 34375760Full record

SynthesisInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients.

Carlos Diaz-Arocutipa, Beatriz Melgar-Talavera, Ángel Alvarado-Yarasca, María M Saravia-Bartra, Pedro Cazorla, Iván Belzusarri, Adrian V Hernandez

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carlos Diaz-ArocutipaVicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru; Programa de Atencion Domiciliaria - EsSalud, Lima, Peru; Asociación para el Desarrollo de la Investigación Estudiantil en Ciencias de la Salud (ADIECS), Lima, Peru. Electronic address: cdiazar@usil.edu.pe.
Beatriz Melgar-TalaveraVicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Ángel Alvarado-YarascaInternational Research Network in Pharmacology and Precision Medicine, Human Medicine, Universidad San Ignacio de Loyola, Lima, Peru.
María M Saravia-BartraInternational Research Network in Pharmacology and Precision Medicine, Human Medicine, Universidad San Ignacio de Loyola, Lima, Peru.
Pedro CazorlaInternational Research Network in Pharmacology and Precision Medicine, Human Medicine, Universidad San Ignacio de Loyola, Lima, Peru; Servicio de Pediatria, Hospital III Suarez-Angamos - EsSalud, Lima, Peru.
Iván BelzusarriInternational Research Network in Pharmacology and Precision Medicine, Human Medicine, Universidad San Ignacio de Loyola, Lima, Peru.
Adrian V HernandezVicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru; Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere is conflicting evidence about the efficacy of statin use in regard to clinical outcomes in patients with coronavirus disease 2019 (COVID-19). A systematic review and meta-analysis was performed to examine the effect of statin use on mortality in COVID-19 patients.

methodsThe electronic databases were searched, from inception to March 3, 2021. Unadjusted and adjusted effect estimates with their 95% confidence intervals (95% CI) were pooled using random-effects models.

resultsTwenty-five cohort studies involving 147 824 patients were included. The mean age of the patients ranged from 44.9 to 70.9 years; 57% of patients were male and 43% were female. The use of statins was not associated with mortality when applying the unadjusted risk ratio (uRR 1.16, 95% CI 0.86-1.57; 19 studies). In contrast, meta-analyses of the adjusted odds ratio (aOR 0.67, 95% CI 0.52-0.86; 11 studies) and adjusted hazard ratio (aHR 0.73, 95% CI 0.58-0.91; 10 studies) showed that statins were independently associated with a significant reduction in mortality. Subgroup analyses showed that only chronic use of statins significantly reduced mortality according to the adjusted models.

conclusionsThe use of statins was found to be associated with a lower risk of mortality in COVID-19 patients based on adjusted effects of cohort studies. However, randomized controlled trials are still needed to confirm these findings.

Indexed as

COVID-19Hydroxymethylglutaryl-CoA Reductase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedRiskSARS-CoV-2Hydroxymethylglutaryl-CoA Reductase InhibitorsCOVID-19MortalityStatinsSystematic review

Identifiers

PMID34375760
PMCPMC8349445

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.